Ngm Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended March 31, 2022.

NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

Moderna

Regeneron Pharmaceuticals

Seagen

TG Therapeutics

After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.

5 Graham's Lost Formula Biotech Stocks to Consider for May

After last year's NASH flop, NGM was written off as a lost cause. The company has been able to turn itself around.

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on two late-breaking poster presentations it will give on Wednesday, April 13, 2022, at the American Association for Cancer Research (AACR) Annual Meeting. NGM Bio will also give an oral presentation on April 10, 2022 at the AACR meeting featuring preclinical data for the lead program in its myeloid checkpoint inhibitor portfolio, NGM707, a dual ITL2/ILT4 antagonist antibody.

NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that abstracts related to all three of the company's myeloid reprogramming and checkpoint inhibition programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will take place April 8 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting

Advanced programs across NGM Bio's pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Novel Immuno-oncology (IO) Panel and will provide an overview of the company and a business update focusing on NGM Bio's wholly-owned oncology portfolio on Monday, March 7, at 10:30 am ET.

NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy (GA) secondary to age-related macular degeneration. NGM Bio is currently evaluating NGM621 in its ongoing Phase 2 CATALINA study and a topline data readout is expected in the fourth quarter of 2022.

NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided an overview of highlights from 2021 and its strategic priorities for 2022.

NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate NGM707, NGM's wholly-owned novel ILT2/ILT4 dual antagonist antibody, in combination with Merck's anti-PD-1 therapy, KEYTRUDA. NGM is currently enrolling patients in the Phase 1/2 trial, initiated in June 2021, to evaluate the potential of NGM707 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced or metastatic solid tumors with elevated expression of ILT2 and ILT4.

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck's KEYTRUDA® (pembrolizumab)

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 2.63% and -1.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

A drop in the overall market provides an opportunity for investors to pounce.

Is Good News Enough for You to Buy NGM on the Dip?

NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced preliminary findings from its ongoing Phase 1a/1b dose-escalation study of NGM120 in solid tumors. Related Link:   Raymond James Upgraded This Biopharma Stock And Sees 44% Upside.

NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial

Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:NGM) to Strong Buy from Outperform with a price target of $39, up from $27, almost 44% upside. Analyst Steven Seedhouse notes the validation of NGM's C3 antibody mechanism and the large potential opportunity for NGM621 in geographic atrophy (GA).

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside

SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other ligands. The announcement coincides with a publication in Cancer Immunology Research, a journal of the American Association for Cancer Research,1 describing NGM's discovery of ILT3's functional ligand, fibronectin, an extracellular matrix protein that forms a fibrillar network within the tumor stroma. This discovery enabled the development of NGM831, which joins NGM's growing portfolio of wholly owned oncology antibody programs, including NGM120 (anti-GFRAL), NGM707 (anti-ILT2/ILT4) and NGM438 (anti-LAIR1).

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -23.08% and -24.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?

NGM Biopharmaceuticals (NGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes NGM Biopharmaceuticals (NGM) a New Buy Stock

Merck

NGM Biopharmaceuticals Inc (NASDAQ: NGM) has amended and restated an agreement with Merck & Co Inc (NYSE: MRK) to extend their ongoing collaboration through March 2024 with a narrower scope.  The collaboration will focus primarily on developing treatments for retinal and cardiovascular & metabolic (CVM) diseases, including heart failure.

NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets

SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known as MSD outside the United States and Canada, to extend their ongoing collaboration through March 2024 but with a narrower scope. NGM disclosed in March 2021 that NGM and Merck were negotiating modifications to certain terms of the agreement to better address their respective evolving priorities. Going forward, the collaboration will focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck retains an option to license those programs being advanced under the amended collaboration. NGM gains worldwide rights to its disclosed oncology portfolio, as well as all preclinical, and current and future research, assets falling outside of the amended collaboration's narrower scope, subject to a low single digit net sales royalty to Merck.

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?

Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceuticals, Inc. ("NGM" or "the Company") (NASDAQ: NGM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. NGM announced on May 24, 2021, that it would be abandoning...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceuticals, Inc. ("NGM" or "the Company") (NASDAQ: NGM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. NGM announced on May 24, 2021, that it would be abandoning...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

News for Ngm Biopharmaceuticals Inc Stock (NGM)